Lexaria Bioscience Expands Global Patent Portfolio to 60 with Six New Grants

Lexaria Bioscience Corp. has reached a significant milestone in its intellectual property strategy, announcing the grant of six new patents that bring its global total to 60 valid patents across major markets. This expansion follows the company's previous patent update on October 9, 2025, and represents continued legal recognition of its innovations in drug delivery technology. The new patents strengthen Lexaria's position in several important therapeutic areas and geographic regions, supporting its commercial objectives.

In patent Family #20, focused on compositions and methods for sublingual delivery of nicotine, Lexaria has received its first patent in Australia, adding to existing grants in the United States, Canada, and Japan. The company achieved another key milestone with its first European Union patent in Family #21, which covers compositions and methods for treating hypertension. Europe represents the second-largest hypertension market globally after the United States, making this patent particularly valuable for future commercial opportunities.

Lexaria's patent Family #24, addressing compositions and methods for treating epilepsy, has been strengthened with two new Australian patents and one new European Union patent. This brings the family's total to six United States patents, four Australian patents, and one European Union patent, creating robust intellectual property protection in this important therapeutic area. Additionally, in Family #27, which covers compositions and methods for treating diabetes, Lexaria has received one new United States patent, bringing the total in this family to two United States patents. This expansion comes at a time when the company has reported recent successes in the GLP-1 sector.

The company's patent development process begins with evaluating initial hypotheses through existing scientific literature, followed by animal and human testing to generate supporting data for patent applications in international markets. Only after patents are granted does Lexaria pursue commercial relationships to exploit its innovations safely. The growing patent portfolio reflects the company's commitment to developing its DehydraTECH drug delivery platform, which improves how various drugs enter the bloodstream through oral delivery by increasing bio-absorption, reducing side effects, and enhancing delivery across the blood-brain barrier.

Separately, Lexaria reminded shareholders to vote in the upcoming annual meeting scheduled for January 27, 2026. Stockholders holding common stock as of December 1, 2025, are entitled to vote, and the company encourages voting on all proposals as recommended by the board of directors. Proxy materials and the annual report are available online at https://www.colonialstock.com/LEXX2026, where shareholders can vote using their control number. The voting deadline is 4:00 PM PT on January 26, 2026. For more information about Lexaria's technology and research, visit https://www.lexariabioscience.com.